Header Logo

Connection

SURENA MATIN to Drug Carriers

Back to Details
This is a "connection" page, showing publications SURENA MATIN has written about Drug Carriers.
SURENA MATIN
Connection Strength
0.158
Drug Carriers
  1. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
    View in: PubMed
    Score: 0.158
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.